Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00096447
Phase
PHASE2
Status
Completed

Conditions

  • Recurrent Endometrial Carcinoma

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib ditosylate — DRUG

Study Details

This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth

Key Dates

Start date
Nov 30, 2004
Status verified
Jul 2019
Primary completion
Mar 31, 2011
Completion
Mar 31, 2011

Study Design

Enrollment
31 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (lapatinib ditosylate)
    Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Percentage of Patients With Progression-free Survival > 6 Months [ Time Frame: For those patients whose disease can be evaluated by physical examination, progression was assessed prior to each 28-day cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle, for up to 5 years. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Gynecologic Oncology GroupPhiladelphiaPennsylvania19103-

Find similar trials in Philadelphia, PA

By research site
Gynecologic Oncology Group· Philadelphia, PA

Related Studies